Clinical trialNCT05687266Active, not recruitingPhase 3Interventional

Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

SponsorAstraZenecaEnrollment1,350NSCLC

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase III, randomized, open-label, multicenter, global study to compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin compared with pembrolizumab in combination with histology-specific platinum-based chemotherapy as first-line treatment of adults with stage IIIB, IIIC, or IV NSCLC without actionable genomic alterations (including sensitizing EGFR mutations, and ALK and ROS1 rearrangements).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Charu Aggarwal
Perelman Center for Advanced Medicine
Study ChairKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

254 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Austria

Research Site
Graz, Austria
Research Site
Rankweil, Austria
Research Site
Vienna, Austria
Research Site
Vienna, Austria

Brazil

Research Site
Blumenau, Brazil
Research Site
Florianópolis, Brazil
Research Site
Fortaleza, Brazil
Research Site
Londrina, Brazil
Research Site
Porto Alegre, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
Taubaté, Brazil
Research Site
Vitória, Brazil

Bulgaria

Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Varna, Bulgaria

Canada

Research Site
Saint John, New Brunswick, Canada
Research Site
Brampton, Ontario, Canada
Research Site
Greater Sudbury, Ontario, Canada
Research Site
Kitchener, Ontario, Canada
Research Site
Newmarket, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Saint-Jérôme, Quebec, Canada
Research Site
Saskatoon, Saskatchewan, Canada

China

Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Changsha, China
Research Site
Changsha, China
Research Site
Chengdu, China
Research Site
Chengdu, China
Research Site
Chongqing, China
Research Site
Guangzhou, China

214 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Carboplatin →Cisplatin →Datopotamab deruxtecan →Durvalumab →Paclitaxel →Pembrolizumab →Pemetrexed →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 29 Dec 2022
Primary completion: 1 Nov 2027
Completion: 1 Nov 2027
Last update posted: 22 Apr 2026
Registered enrollment: 1,350
Registry id: NCT05687266

Cross-registrations

EU-CTR / CTIS (EudraCT)2021-004606-21

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.